Ocular Therapeutix (NSDQ:OCUL) said today that it dosed the first patient in a study of its OTX-TKI tyrosine kinase inhibitor implant.
The Phase I trial is slated to assess the bioresorbable device’s safety, durability and tolerability in people with wet age-related macular degeneration.
Get the full story at our sister site, Drug Delivery Business News.
The post Ocular Therapeutix doses first wet-AMD patient in implant trial appeared first on MassDevice.